Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure
Executive Summary
Pfizer will reorganize from two business units to three, creating a separate Consumer Healthcare unit alongside Innovative Medicines and Established Medicines. The changes will not be effective until the beginning of 2019.
You may also be interested in...
Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm
After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?
Pfizer On Reorganizing, M&A And Investing In Internal R&D
The big pharma's leadership weighs in on why it made sense to organize biosimilars under innovative medicines, why it is investing more in internal R&D, and why tuck-in deals are more appealing than transformative M&A.
Pfizer On Reorganizing, M&A And Investing In Internal R&D
The big pharma's leadership weighs in on why it made sense to organize biosimilars under innovative medicines, why it is investing more in internal R&D, and why tuck-in deals are more appealing than transformative M&A.